Abstract

Primary tumors are often heterogeneous, composed of therapy-sensitive and emerging therapy-resistant cancer cells. Interestingly, treatment of therapy-sensitive tumors in heterogeneous tumor microenvironments results in apoptosis of therapy-resistant tumors. In this study, we identify a prostate apoptosis response-4 (Par-4) amino-terminal fragment (PAF) that is released by diverse therapy-sensitive cancer cells following therapy-induced caspase cleavage of the tumor suppressor Par-4 protein. PAF caused apoptosis in cancer cells resistant to therapy and inhibited tumor growth. A VASA segment of Par-4 mediated its binding and degradation by the ubiquitin ligase Fbxo45, resulting in loss of Par-4 proapoptotic function. Conversely, PAF, which contains this VASA segment, competitively bound to Fbxo45 and rescued Par-4–mediated induction of cancer cell–specific apoptosis. Collectively, our findings identify a molecular decoy naturally generated during apoptosis that inhibits a ubiquitin ligase to overcome therapy resistance in tumors.

Document Type

Article

Publication Date

8-2017

Notes/Citation Information

Published in Cancer Research, v. 77, issue 15, p. 4039-4050.

© 2017 American Association for Cancer Research

The copyright holder has granted the permission for posting the article here.

The document available for download is the authors' post-peer-review final draft of the article.

Digital Object Identifier (DOI)

https://doi.org/10.1158/0008-5472.CAN-16-1970

Funding Information

V.M. Rangnekar was recipient of NIH grants R01CA187273, R01CA165469, and R21CA179283.

Related Content

Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

169293_3_supp_4054972_xqrx44.pdf (888 kB)
Supplementary Data

Share

COinS